TY - JOUR
T1 - Older versus younger adults with gastric cancer receiving perioperative treatment
T2 - Results from the CRITICS trial
AU - Slagter, Astrid E.
AU - Tudela, Benjamin
AU - van Amelsfoort, Romy M.
AU - Sikorska, Karolina
AU - van Sandick, Johanna W.
AU - van de Velde, Cornelis J.H.
AU - van Grieken, Nicole C.T.
AU - Lind, Pehr
AU - Nordsmark, Marianne
AU - Putter, Hein
AU - Hulshof, Maarten C.C.M.
AU - van Laarhoven, Hanneke W.M.
AU - Grootscholten, Cecile
AU - Braak, Jeffrey P.B.M.
AU - Meershoek-Klein Kranenbarg, Elma
AU - Jansen, Edwin P.M.
AU - Cats, Annemieke
AU - Verheij, Marcel
N1 - Funding Information: This study was supported by the Dutch Cancer Society , the Dutch Colorectal Cancer Group and Hoffmann La Roche . The funding sources had no role in the design, collection, analysis and interpretation of the data. Funding Information: N.C.T. van Grieken reported receiving grants from the Dutch Cancer Society and The Netherlands Organisation for Health Research and Development , and serving on an advisory board for Bristol-Myers Squibb and Merck Sharp & Dohme. H.W.M. van Laarhoven reported receiving grants/medication support from Bayer , BMS , Celgene , Janssen , Lilly , Nordic Pharma , Philips , Roche , Servier , and serving on an advisory board for BMS, Lilly, MSD, Nordic Pharma, Novartis, Servier E.P.M. Jansen, A. Cats and M. Verheij reported receiving grants from the Dutch Cancer Society , the Dutch Colorectal Cancer Group and Hoffmann La Roche. All remaining authors have declared no conflicts of interest. Publisher Copyright: © 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/5
Y1 - 2020/5
N2 - Aim: To evaluate treatment-related toxicity, treatment compliance, surgical complications and event-free survival (EFS) in older (≥70 years) versus younger (<70 years) adults who underwent perioperative treatment for gastric cancer. Methods: In the CRITICS trial, 788 patients with resectable gastric cancer were randomised before start of any treatment and received preoperative chemotherapy (3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine), followed by surgery, followed by either postoperative chemotherapy or chemoradiotherapy (45Gy + cisplatin + capecitabine). Results: 172 (22%) patients were older adults. During preoperative chemotherapy, 131 (77%) older adults versus 380 (62%) younger adults experienced severe toxicity (p < 0.001); older adults received significantly lower relative dose intensities (RDIs) for all chemotherapeutic drugs. Equal proportions of older versus younger adults underwent curative surgery: 137 (80%) versus 499 (81%), with comparable postoperative complications and postoperative mortality. Postoperative therapy after curative surgery started in 87 (64%) older adults versus 391 (78%) younger adults (p < 0.001). Incidence of severe toxicity during postoperative chemotherapy was 22 (54%) in older adults versus 113 (59%) in younger adults (p = 0.541); older adults received significantly lower RDIs for all chemotherapeutic drugs. Severe toxicity rates for postoperative chemoradiotherapy were 22 (48%) older adults versus 89 (45%) for younger adults (p = 0.703), with comparable chemotherapy RDIs and radiotherapy dose. Two-year EFS was 53% for older adults versus 51% for younger adults. Conclusion: Perioperative treatment compliance, especially in the postoperative phase, was poorer in older adults compared with younger adults. As comparable proportions of patients underwent curative surgery, future studies should focus on neo-adjuvant treatment. Trial registration: ClinicalTrials.gov identifier: NCT00407186. EudraCT number: 2006–00413032.
AB - Aim: To evaluate treatment-related toxicity, treatment compliance, surgical complications and event-free survival (EFS) in older (≥70 years) versus younger (<70 years) adults who underwent perioperative treatment for gastric cancer. Methods: In the CRITICS trial, 788 patients with resectable gastric cancer were randomised before start of any treatment and received preoperative chemotherapy (3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine), followed by surgery, followed by either postoperative chemotherapy or chemoradiotherapy (45Gy + cisplatin + capecitabine). Results: 172 (22%) patients were older adults. During preoperative chemotherapy, 131 (77%) older adults versus 380 (62%) younger adults experienced severe toxicity (p < 0.001); older adults received significantly lower relative dose intensities (RDIs) for all chemotherapeutic drugs. Equal proportions of older versus younger adults underwent curative surgery: 137 (80%) versus 499 (81%), with comparable postoperative complications and postoperative mortality. Postoperative therapy after curative surgery started in 87 (64%) older adults versus 391 (78%) younger adults (p < 0.001). Incidence of severe toxicity during postoperative chemotherapy was 22 (54%) in older adults versus 113 (59%) in younger adults (p = 0.541); older adults received significantly lower RDIs for all chemotherapeutic drugs. Severe toxicity rates for postoperative chemoradiotherapy were 22 (48%) older adults versus 89 (45%) for younger adults (p = 0.703), with comparable chemotherapy RDIs and radiotherapy dose. Two-year EFS was 53% for older adults versus 51% for younger adults. Conclusion: Perioperative treatment compliance, especially in the postoperative phase, was poorer in older adults compared with younger adults. As comparable proportions of patients underwent curative surgery, future studies should focus on neo-adjuvant treatment. Trial registration: ClinicalTrials.gov identifier: NCT00407186. EudraCT number: 2006–00413032.
KW - Chemoradiotherapy
KW - Chemotherapy
KW - Older adults
KW - Resectable gastric cancer
UR - http://www.scopus.com/inward/record.url?scp=85081994782&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejca.2020.02.008
DO - https://doi.org/10.1016/j.ejca.2020.02.008
M3 - Article
C2 - 32208351
SN - 0959-8049
VL - 130
SP - 146
EP - 154
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -